Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Total Current Liabilities
All obligations due within one year.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Total Current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total current liabilities rises 187.0% from a year ago
Total current liabilities stood at $34.81M at the end of Q4 FY2025, up 187.0% from a year earlier. Over 3 fiscal years it compounded at +39.2% a year.
Context
- Total current liabilities amounted to 167.5% of total assets at the end of Q4 FY2025, down 23.0 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +187.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 34.81M USD
- Year-over-year change
- +187.0%
- 4-year CAGR
- +53.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.81M | +187.0% |
| FY2024 | 2024-12-31 | 12.13M | -14.9% |
| FY2023 | 2023-12-31 | 14.26M | +10.5% |
| FY2022 | 2022-12-31 | 12.91M | +105.1% |
| FY2021 | 2021-12-31 | 6.29M | — |
Total Current Liabilities vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +187.0% is the highest of 11, against a peer median of +46.0%.
- Total current liabilities amounts to 167.5% of total assets for MENS, versus a peer median of 9.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.64B CNY | +41.0% | +23.1% | 41.5% |
| Mar 2026 | $325M USD | +11.4% | +13.7% | 25.1% | |
| Sep 2026 | $289.6M USD | -33.2% | +28.8% | 17.2% | |
| Sep 2026 | $210.91M USD | +56.1% | +4.0% | 24.9% | |
| Jun 2026 | $86.87M USD | +117.5% | +85.8% | 10.5% | |
| Jun 2026 | $78.03M USD | +88.1% | +21.7% | 7.8% | |
| Sep 2026 | $46.43M USD | +52.1% | +26.0% | 4.4% | |
| Sep 2026 | $45.3M USD | +18.2% | +22.6% | 3.8% | |
| Jun 2026 | $37.51M USD | +18.9% | +40.9% | 2.8% | |
| Mar 2026 | $36.57M USD | +51.1% | +3.8% | 5.7% | |
| Dec 2025 | $34.81M USD | +187.0% | +39.2% | 167.5% | |
| Peer median (excluding MENS) | — | +46.0% | +22.8% | 9.2% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 551K | 718K | 177K | 98K | 1.18M |
| Short-term Investments | 1.83M | 94K | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 13.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 263K | 1.65M | 1.66M | 108K | 854K |
| Total Current Assets | 2.65M | 2.46M | 1.84M | 206K | 15.54M |
| Property, Plant & Equipment (Net) | 6.78M | 6M | 3.54M | 3.19M | 5.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8K | 283K | 2.87M | 2.97M | 6K |
| Total Non-current Assets | 6.78M | 6.28M | 6.41M | 6.16M | 5.24M |
| Total Assets | 9.43M | 8.75M | 8.25M | 6.37M | 20.78M |
| Account Payables | 46K | 4K | 2K | 3K | 2K |
| Short-term Debt | 4.93M | 7.65M | 7.97M | 7.28M | 8.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23K | 4.22M | 4.99M | 3.33M | 26.31M |
| Total Current Liabilities | 6.29M | 12.91M | 14.26M | 12.13M | 34.81M |
| Long-term Debt | 6.26M | 6.32M | 8.52M | 10.68M | 10.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.86M | 19.04M | 19.47M | 20.06M | 688K |
| Total Non-current Liabilities | 26.46M | 25.47M | 28.06M | 30.76M | 10.87M |
| Total Liabilities | 32.76M | 38.38M | 42.32M | 42.89M | 45.68M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (19.03M) | (25.66M) | (30.06M) | (33.08M) | (37.75M) |
| Accumulated OCI | 266K | 590K | 548K | 1.12M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.33M) | (29.63M) | (34.07M) | (36.52M) | (24.91M) |
| Total Debt | 11.79M | 14.25M | 16.69M | 18.14M | 18.55M |
| Net Debt | 11.24M | 13.53M | 16.51M | 18.04M | 17.37M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.